News Releases

News Releases
Events
Presentations

Year

September 2, 2020

Bioventus Reports First Use of its SIGNAFUSE Bioactive Bone Graft in Strip Format

DURHAM, NC – September 2, 2020 – Bioventus is sharing results of the first in-patient use of its new SIGNAFUSE Bioactive Bone Graft strips. Rick Placide, M.D. of VCU Health in Richmond, VA, performed a posterolateral lumbar fusion (PLF) and placed the SIGNAFUSE strips in the posterolateral gutters

August 24, 2020

Bioventus Appoints Katrina Church Chief Compliance Officer

DURHAM, NC – August 24, 2020 – Bioventus , a global leader in orthobiologic solutions, has appointed Katrina Church as its Chief Compliance Officer, effective August 24, 2020. Church brings more than 20 years of experience counseling public and private companies to ensure the highest compliance

August 13, 2020

Hyaluronic Acid Provides Knee OA Pain Relief with Lower Costs, Fewer Adverse Outcomes vs. Corticosteroids or Knee Arthroplasty

DURHAM, NC – August 13, 2020 – Intra-articular hyaluronic acid (IHA) knee osteoarthritis (OA) pain relief treatments had lower total medical care costs vs. patients treated with intra-articular corticosteroids (ICS) or total knee arthroplasty (TKA). This according to a retrospective study,

July 16, 2020

Bioventus Makes $15 Million Equity Investment in CartiHeal with an Agreed Option Structure to Acquire Company Upon Milestone Achievements

KFAR SABA, ISRAEL and DURHAM, NC– July 16, 2020 – CartiHeal , developer of the proprietary Agili™-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured an additional $15 million equity investment from Bioventus , a global leader in orthobiologics.

June 25, 2020

Bioventus Receives FDA Clearance of Strip Format of its SIGNAFUSE Bioactive Bone Graft

DURHAM, NC – June 25, 2020 – Bioventus , a global leader in orthobiologic solutions, is launching its SIGNAFUSE Bioactive Bone Graft in a new strip format. The strips consist of 55% bioglass by weight and have been shown to induce higher levels of osteoblast differentiation compared to other

June 15, 2020

Bioventus Selects Bazis NN as Distributor of DUROLANE in Russia

HOOFDDORP, THE NETHERLANDS – June 15, 2020 – Bioventus , a global leader in orthobiologic solutions, has selected Bazis NN as its authorized distributor for DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment. OA involves the breakdown, or degeneration, of cartilage and the

March 25, 2020

Bioventus Announces Change in Chief Executive Officer, Ken Reali Appointed to Succeed Tony Bihl Who Will Retire

DURHAM, NC – March 25, 2020 – Tony Bihl , CEO of Bioventus , a global leader in orthobiologic solutions, is electing to retire on April 30, 2020. As a result, the Bioventus Board of Managers has unanimously appointed Ken Reali, former President and CEO of Clinical Innovations, LLC, to assume the

February 24, 2020

Bioventus Recognizes 25 Years of Bone Healing from Exogen

DURHAM, NC – February 24, 2020 – Bioventus , a global leader in orthobiologic solutions, is recognizing 25 years of proven bone healing with its EXOGEN Ultrasound Bone Healing System . EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural bone healing process and

February 10, 2020

Bioventus Updates US Label for EXOGEN Ultrasound Bone Healing System

DURHAM, NC – February 10, 2020 – Bioventus , a global leader in orthobiologic solutions, has updated the indications for use for its EXOGEN Ultrasound Bone Healing System . EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural bone healing process and promote

December 18, 2019

Bioventus to Provide Blue Cross Blue Shield of Michigan with Preferred Options for Knee Osteoarthritis Patients, Products include DUROLANE®, GELSYN-3® and SUPARTZ FX®

DURHAM, NC – December 18, 2019 – Beginning January 1, 2020 Bioventus , a global leader in orthobiologic solutions, has secured preferred access for Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients to DUROLANE , GELSYN-3 and SUPARTZ FX to treat knee osteoarthritis (OA)

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Current page 11
Page 12
Page 13
Next page
Last page

Displaying 101 - 110 of 126